☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Moderate to Severe
AbbVie's Rinvoq (upadacitinib) Receives EC's Approval for the Treatment of Moderate to Severe Atopic Dermatitis
August 25, 2021
Pfizer Reports Results of Abrocitinib in Fifth P-lll JADE REGIMEN Across Different Dosing Regimens
November 12, 2020
Lilly's Olumiant (baricitinib) Receives CHMP's Positive Opinion for Moderate to Severe Atopic Dermatitis
September 21, 2020
LEO Reports the US FDA's Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis
July 10, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.